title: Targeting the mTOR signaling pathway in neuroendocrine tumors.
abstract: Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies characterized by variable but most often indolent biologic behavior. Well-differentiated NETs can be broadly classified as either carcinoid or pancreatic NET. Although they have similar characteristics on routine histologic evaluation, the 2 tumor subtypes have different biology and respond differently to treatment, with most therapeutic agents demonstrating higher response rates in pancreatic NETs compared with carcinoid. Until recently, systemic treatment options for patients with advanced NETs were limited. However, improvements in our understanding of signaling pathways involved in the pathogenesis, growth, and spread of NETs have translated into an expansion of treatment options. Aberrant signaling through the mechanistic pathway of rapamycin (mTOR) pathway has been implicated in neuroendocrine tumorigenesis. Additionally, altered expression of mTOR pathway components has been observed in NETs and has been associated with clinical outcomes. Targeting the mTOR pathway has emerged as an effective treatment strategy in the management of advanced NETs. In a randomized, placebo-controlled study of patients with advanced pancreatic NET, treatment with the mTOR inhibitor everolimus was associated with improved progression-free survival (PFS). Largely based upon these data, everolimus has been approved in the United States and Europe for the treatment of patients with advanced pancreatic NET. The activity of everolimus remains under investigation in patients with carcinoid tumors. In a randomized study of patients with advanced carcinoid tumors associated with carcinoid syndrome, the addition of everolimus to octreotide was associated with improved PFS compared with octreotide. However, the results did not meet the prespecified level of statistical significance based on central review of radiographic imaging. Results from a randomized study examining the efficacy of everolimus in patients with nonfunctional gastrointestinal and lung NETs are awaited. In addition, further investigation is needed to determine whether primary tumor site or other clinical and molecular factors can impact response to mTOR inhibition. Although everolimus can slow tumor progression, significant tumor reduction is rarely obtained. Targeting multiple signaling pathways is a treatment strategy that may provide better tumor control and overcome resistance mechanisms involved with targeting a single pathway. Results of ongoing and future studies will provide important information regarding the added benefit of combining mTOR inhibitors with other targeted agents, such as VEGF pathway inhibitors, and cytotoxic chemotherapy in the treatment of advanced NETs.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA, jang@partners.org.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Chan
authors.forename: Matthew
authors.initials: M
authors.lastname: Kulke
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D058990:Molecular Targeted Therapy; D018358:Neuroendocrine Tumors / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects*; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D058570:TOR Serine-Threonine Kinases
references.citation: Pancreas. 2010 Aug;39(6):707-12
references.pmid: 20664470
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8
references.pmid: 15937108
references.citation: Nat Cell Biol. 2004 Nov;6(11):1122-8
references.pmid: 15467718
references.citation: Nat Cell Biol. 2002 Sep;4(9):658-65
references.pmid: 12172554
references.citation: J Gastrointest Surg. 2009 Oct;13(10):1773-80
references.pmid: 19582519
references.citation: Cancer. 2007 Apr 15;109(8):1478-86
references.pmid: 17340592
references.citation: Nat Cell Biol. 2002 Sep;4(9):648-57
references.pmid: 12172553
references.citation: Endocr Relat Cancer. 2011 Jan 13;18(1):181-92
references.pmid: 21159731
references.citation: N Engl J Med. 2011 May 12;364(19):1873; author reply 1873-5
references.pmid: 21561355
references.citation: Nat Rev Mol Cell Biol. 2009 May;10(5):307-18
references.pmid: 19339977
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1316-23
references.pmid: 18323556
references.citation: Int J Cancer. 2011 Mar 1;128(5):1045-56
references.pmid: 20473929
references.citation: J Clin Oncol. 2009 May 1;27(13):2278-87
references.pmid: 19332717
references.citation: J Clin Oncol. 2013 Sep 20;31(27):3418-25
references.pmid: 23980085
references.citation: J Clin Oncol. 2010 Jan 10;28(2):245-55
references.pmid: 19917848
references.citation: Cell. 2012 Apr 13;149(2):274-93
references.pmid: 22500797
references.citation: N Engl J Med. 2011 Feb 10;364(6):501-13
references.pmid: 21306237
references.citation: Cancer. 2011 Jan 15;117(2):268-75
references.pmid: 20824724
references.citation: Br J Cancer. 2006 Nov 6;95(9):1148-54
references.pmid: 17031397
references.citation: Ann Oncol. 2013 Jan;24(1):152-60
references.pmid: 22967994
references.citation: Cancer. 2013 Sep 1;119(17):3212-8
references.pmid: 23733618
references.citation: Clin Cancer Res. 2009 Jan 1;15(1):338-45
references.pmid: 19118063
references.citation: Oncologist. 2013;18(1):46-53
references.pmid: 23263288
references.citation: Clin Cancer Res. 2007 May 15;13(10):2986-91
references.pmid: 17505000
references.citation: Science. 2011 Mar 4;331(6021):1199-203
references.pmid: 21252315
references.citation: Am J Pathol. 2000 Oct;157(4):1097-103
references.pmid: 11021813
references.citation: Curr Opin Oncol. 2009 Jan;21(1):29-33
references.pmid: 19125015
references.citation: N Engl J Med. 1999 Mar 18;340(11):858-68
references.pmid: 10080850
references.citation: N Engl J Med. 2011 Feb 10;364(6):514-23
references.pmid: 21306238
references.citation: J Clin Endocrinol Metab. 2012 Mar;97(3):727-37
references.pmid: 22170729
references.citation: Cancer Chemother Pharmacol. 2013 May;71(5):1241-6
references.pmid: 23475104
references.citation: Cancer Res. 2013 Mar 1;73(5):1449-53
references.pmid: 23436795
references.citation: Cancer Res. 1998 Aug 15;58(16):3706-11
references.pmid: 9721882
references.citation: J Clin Oncol. 2004 Dec 1;22(23):4762-71
references.pmid: 15570077
references.citation: J Clin Oncol. 2008 Sep 10;26(26):4311-8
references.pmid: 18779618
references.citation: N Engl J Med. 2009 Jan 8;360(2):195-7
references.pmid: 19129539
references.citation: Acta Oncol. 2007;46(6):741-6
references.pmid: 17653895
references.citation: J Clin Oncol. 2010 Jan 1;28(1):69-76
references.pmid: 19933912
references.citation: Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74
references.pmid: 17977644
references.citation: Mol Cell. 2002 Sep;10(3):457-68
references.pmid: 12408816
references.citation: Cancer Res. 2006 Feb 1;66(3):1500-8
references.pmid: 16452206
references.citation: Lancet. 2011 Dec 10;378(9808):2005-2012
references.pmid: 22119496
references.citation: Mol Cancer Ther. 2005 Oct;4(10):1533-40
references.pmid: 16227402
references.citation: Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
references.pmid: 21157483
references.citation: Oncologist. 2011;16(6):783-7
references.pmid: 21482586
references.citation: Histopathology. 1998 Feb;32(2):133-8
references.pmid: 9543669
references.citation: J Clin Oncol. 2011 Mar 1;29(7):934-43
references.pmid: 21263089
references.citation: Endocr Relat Cancer. 2008 Mar;15(1):257-66
references.pmid: 18310292
references.citation: J Cell Sci. 2013 Apr 15;126(Pt 8):1713-9
references.pmid: 23641065
references.citation: Science. 2005 Feb 18;307(5712):1098-101
references.pmid: 15718470
references.citation: Semin Oncol. 2013 Feb;40(1):37-44
references.pmid: 23391111
references.citation: Mod Pathol. 2003 Jul;16(7):652-9
references.pmid: 12861060
references.citation: Mol Cell. 2002 Jul;10(1):151-62
references.pmid: 12150915
references.citation: N Engl J Med. 1992 Feb 20;326(8):519-23
references.pmid: 1310159
references.citation: Clin Cancer Res. 2003 Apr;9(4):1469-73
references.pmid: 12684421
references.citation: Cell. 2006 Feb 10;124(3):471-84
references.pmid: 16469695
references.citation: J Clin Oncol. 2009 Oct 1;27(28):4656-63
references.pmid: 19704057
references.citation: Cancer Cell. 2011 Jan 18;19(1):58-71
references.pmid: 21215704